SML2401
Imeglimin hydrochloride
≥98% (HPLC), powder, anti-hyperglycemic compound
同義詞:
(6R)-1,6-dihydro-N,N,6-trimethyl-1,3,5-Triazine-2,4-diamine Hydrochloride,, (6R)-3,6-Dihydro-N2,N2,6-trimethyl-1,3,5-triazine-2,4-diamine, EMD 387008 Hydrochloride, EMD-387008 Hydrochloride, R-(4-Imino-6-methyl-1,4,5,6-tetrahydro-[1,3,5]trazin-2-yl)dimethylamine Hydrochloride
登入查看組織和合約定價
全部照片(1)
About This Item
經驗公式(希爾表示法):
C6H13N5 · xHCl
CAS號碼:
分子量::
155.20 (free base basis)
分類程式碼代碼:
12352200
NACRES:
NA.77
推薦產品
產品名稱
Imeglimin hydrochloride, ≥98% (HPLC)
品質等級
化驗
≥98% (HPLC)
形狀
powder
儲存條件
desiccated
顏色
white to beige
溶解度
H2O: 2 mg/mL, clear
儲存溫度
2-8°C
SMILES 字串
Cl.N1[C@@H](N=C(N=C1N(C)C)N)C
InChI
1S/C6H13N5.ClH/c1-4-8-5(7)10-6(9-4)11(2)3;/h4H,1-3H3,(H3,7,8,9,10);1H/t4-;/m1./s1
InChI 密鑰
UXHLCYMTNMEXKZ-PGMHMLKASA-N
生化/生理作用
Glucose-lowering agent that appears to target mitochondrial bioenergetics
Imeglimin is a first-in-class oral glucose-lowering agent whose mechanism of action targets mitochondrial bioenergetics, resulting in increased insulin secretion in response to glucose, improved glucose uptake by skeletal muscle, and suppression of gluconeogenesis. Imeglimin has been shown to decrease reactive oxygen species overproduction and delay mPTP opening, preventing cell death during oxidative stress, protecting beta-cells. In an animal model, it has been shown to reduce metabolic syndrome-related diabetic cardiomyopathy.
儲存類別代碼
11 - Combustible Solids
水污染物質分類(WGK)
WGK 3
閃點(°F)
Not applicable
閃點(°C)
Not applicable
P577 Short- and long-term imeglimin treatment reduces metabolic syndrome-related diabetic cardiomyopathy
Lachaux M, Hamzaoui M, Nicol L, Fouqueray P, Bolze S, Hallakou-Bozec S, Richard V, Mulder P
European Heart Journal, 38 (2017)
D Detaille et al.
Cell death discovery, 2, 15072-15072 (2016-08-24)
Imeglimin is the first in a new class of oral glucose-lowering agents, having recently completed its phase 2b trial. As Imeglimin did show a full prevention of β-cell apoptosis, and since angiopathy represents a major complication of diabetes, we studied
我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.
聯絡技術服務